✉ Email this page to a colleague
« Back to Dashboard
SP2086 is an investigational drug.
There have been 17 clinical trials for SP2086. The most recent clinical trial was a Phase 2 trial, which was initiated on October 15th 2021.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Renal Insufficiency. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd. and [disabled in preview].
There are four US patents protecting this investigational drug and forty-seven international patents.
Recent Clinical Trials for SP2086
|Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes||Jiangsu HengRui Medicine Co., Ltd.||Phase 3|
|The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
|The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
Top disease conditions for SP2086
Top clinical trial sponsors for SP2086
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SP2086||See Plans and Pricing||Tetrahydro-imidazo[1,5-.alpha.]pyrazine derivatives, preparation process and medicinal use thereof||Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, CN) Shanghai Hengrui Pharmaceutical Co. Ltd. (Shanghai, CN)||See Plans and Pricing|
|SP2086||See Plans and Pricing||Pharmaceutical composition for treatment of type 2 diabetes||Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, CN)||See Plans and Pricing|
|SP2086||See Plans and Pricing||Tetrahydro-imidazo[1,5-.alpha.] pyrazine derivatives, preparation process and medicinal use thereof||Jiangsu Hengrui Medicine Co., Ltd. (Jiangsu, CN)||See Plans and Pricing|
|SP2086||See Plans and Pricing||Salts of methyl (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,- 7,8-tetrahydro-imidazo[1,5-A]pyrazine-1-carboxylate||Jiangsu Hengrui Medicine Co., Ltd. (Jiangsu, CN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SP2086||Australia||AU2008342461||2027-12-26||See Plans and Pricing|
|SP2086||Brazil||BRPI0821440||2027-12-26||See Plans and Pricing|
|SP2086||Canada||CA2706735||2027-12-26||See Plans and Pricing|
|SP2086||China||CN101468988||2027-12-26||See Plans and Pricing|
|SP2086||China||CN101641361||2027-12-26||See Plans and Pricing|
|SP2086||European Patent Office||EP2230241||2027-12-26||See Plans and Pricing|
|SP2086||Spain||ES2529435||2027-12-26||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|